Champions Oncology, Inc., formerly known as Champions Biotechnology, Inc., engages in the development of advanced technology solutions to personalize the development and use of oncology drugs. The Company's Tumorgraft Technology Platform is a novel approach to personalizing cancer care based upon the implantation of human tumors in immune deficient mice followed by propagation of the resulting engraftments. This technology can evaluate tumor sensitivity/resistance to various single, combination standard and novel chemotherapy agents. Champions Oncology, Inc. is based in Baltimore, Maryland.
| Revenue (Most Recent Fiscal Year) | $50.15M |
| Net Income (Most Recent Fiscal Year) | $-7.28M |
| PE Ratio (Current Year Earnings Estimate) | -- |
| PE Ratio (Trailing 12 Months) | 14.05 |
| PEG Ratio (Long Term Growth Estimate) | -- |
| Price to Sales Ratio (Trailing 12 Months) | 1.46 |
| Price to Book Ratio (Most Recent Quarterly Book Value per Share) | 15.62 |
| Price to Cash Ratio (Most Recent Annual Cash Flow per Share) | -- |
| Pre-Tax Margin (Trailing 12 Months) | 10.92% |
| Net Margin (Trailing 12 Months) | 10.97% |
| Return on Equity (Trailing 12 Months) | 656.65% |
| Return on Assets (Trailing 12 Months) | 24.04% |
| Current Ratio (Most Recent Fiscal Quarter) | 0.99 |
| Quick Ratio (Most Recent Fiscal Quarter) | 0.99 |
| Debt to Common Equity (Most Recent Fiscal Quarter) | 0.00 |
| Inventory Turnover (Trailing 12 Months) | -- |
| Book Value per Share (Most Recent Fiscal Quarter) | $-0.14 |
| Earnings per Share (Most Recent Fiscal Quarter) | -- |
| Earnings per Share (Most Recent Fiscal Year) | -- |
| Diluted Earnings per Share (Trailing 12 Months) | $0.44 |
| Exchange | NASDAQ |
| Sector | Healthcare |
| Industry | Biotechnology |
| Common Shares Outstanding | 13.83M |
| Free Float | 7.33M |
| Market Capitalization | $85.45M |
| Average Volume (Last 20 Days) | 0.03M |
| Beta (Past 60 Months) | 0.51 |
| Percentage Held By Insiders (Latest Annual Proxy Report) | 46.98% |
| Percentage Held By Institutions (Latest 13F Reports) | 41.30% |
| Annual Dividend (Based on Last Quarter) | $0.00 |
| Dividend Yield (Based on Last Quarter) | 0.00% |